Innate immunity: the first line of defense against SARS-CoV-2
MS Diamond, TD Kanneganti - Nature immunology, 2022 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute
respiratory syndrome coronavirus (SARS-CoV)-2, continues to cause substantial morbidity …
respiratory syndrome coronavirus (SARS-CoV)-2, continues to cause substantial morbidity …
The biological and clinical significance of emerging SARS-CoV-2 variants
The past several months have witnessed the emergence of SARS-CoV-2 variants with novel
spike protein mutations that are influencing the epidemiological and clinical aspects of the …
spike protein mutations that are influencing the epidemiological and clinical aspects of the …
An infectious SARS-CoV-2 B. 1.1. 529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
The emergence of the highly transmissible B. 1.1. 529 Omicron variant of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …
[HTML][HTML] Inflammasome activation in infected macrophages drives COVID-19 pathology
Severe COVID-19 is characterized by persistent lung inflammation, inflammatory cytokine
production, viral RNA and a sustained interferon (IFN) response, all of which are …
production, viral RNA and a sustained interferon (IFN) response, all of which are …
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry
distinct spike mutations resulting in escape from antibodies induced by previous infection or …
distinct spike mutations resulting in escape from antibodies induced by previous infection or …
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
An ideal therapeutic anti-SARS-CoV-2 antibody would resist viral escape,–, have activity
against diverse sarbecoviruses,,–, and be highly protective through viral neutralization,,–and …
against diverse sarbecoviruses,,–, and be highly protective through viral neutralization,,–and …
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
YM Loo, PM McTamney, RH Arends… - Science translational …, 2022 - science.org
Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines, there remains a need for more prevention and treatment options for individuals …
vaccines, there remains a need for more prevention and treatment options for individuals …
After the pandemic: perspectives on the future trajectory of COVID-19
There is a realistic expectation that the global effort in vaccination will bring the pandemic
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) under control …
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) under control …
The humoral response and antibodies against SARS-CoV-2 infection
Two and a half years into the COVID-19 pandemic, we have gained many insights into the
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …
Monoclonal antibody therapies against SARS-CoV-2
Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …